Clinical trial
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
NCT01197378 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis
- Lead sponsor
- Amgen
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 27, 2010
- Completion date
- June 26, 2017
- Enrollment
- 60 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.